Regarding MSBs announcement of data presented at the 62th ASH Annual General Meeting there is reference in the presentation of MSB having recently reported the results from the phase3 pivotal single arm study of remestemcel-L, human, culture-expanded, allogeneic mesenchymal stromal cells as first line therapy after failure to respond to steroids (NCT02336230).
When exactly was the referred to recent reporting of results? In particular, was it pre or post MSB’s please explain sit-down with the FDA regarding the CR letter?
Regarding MSBs announcement of data presented at the 62th ASH...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |